Personal mRNA vaccine after lung cancer surgery
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a personalized mRNA vaccine made from your tumor's unique mutations. It is given after surgery to try to train your immune system to fight any remaining cancer cells, with the goal of preventing the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had surgery to remove your lung cancer and it was confirmed to be non-small cell lung cancer.
- You have not tested positive for EGFR or ALK gene changes.
- You are well enough to be up and about (ECOG score 0 or 1) and expected to live at least 6 months.
- You have no signs of cancer on scans (CT, MRI) within 14 days before the first dose.
- You have no active autoimmune diseases, tuberculosis, hepatitis B or C, HIV, and no history of organ or stem cell transplant.
- You must agree to use birth control if you or your partner are of childbearing age.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized mRNA vaccine (made from your own tumor's genetic fingerprint) combined with an immunotherapy drug called adebrelimab. The goal is to see if this combination can help prevent lung cancer from coming back or slow its growth.
This trial tests a personalized mRNA vaccine made from your tumor's unique markers (neoantigens) to train your immune system to fight cancer. It is for people with advanced solid tumors who have not had gene therapy and are healthy enough for the vaccine.
This trial tests a personalized mRNA vaccine (RH125) designed to train your immune system to attack your cancer. It is for people with advanced solid tumors that have not responded to standard treatments, and it aims to see if the vaccine is safe and helpful.
This trial tests a personalized cancer vaccine, given alone or with an immunotherapy drug called toripalimab, in people with non-small cell lung cancer (NSCLC) who have had surgery and are getting adjuvant therapy (treatment to prevent the cancer from coming back). The goal is to see if the vaccine is safe and may help the immune system fight any remaining cancer cells.
This study tests a combination of a personalized vaccine made from your tumor's unique markers, a type of immunotherapy (PD-1 inhibitor), and radiation. The goal is to see if this mix can work better for advanced lung cancer that has progressed after initial treatment.
This trial tests a new inhaled mRNA therapy that may help your immune system fight cancer. It is for people with advanced lung cancer or cancer that has spread to the lungs when standard treatments have stopped working.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.